12,491 results match your criteria Annals Of Oncology[Journal]

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.

Ann Oncol 2022 Jun 10. Epub 2022 Jun 10.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, USA.

Background: COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible to disruption by the pandemic, but few studies have evaluated the impact of the pandemic on clinical trial conduct.

Patients And Methods: This prospective, multicenter study assesses the impact of the pandemic on therapeutic clinical trials at two large academic centers in the Northeastern United States between December 2019 and June 2021. Read More

View Article and Full-Text PDF

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

Ann Oncol 2022 Jun 15. Epub 2022 Jun 15.

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia.

Background: Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) is limited. We determined the efficacy of ICIs in MM, analysed by primary site and ethnicity/race. Read More

View Article and Full-Text PDF

In the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score.

Ann Oncol 2022 Jun 15. Epub 2022 Jun 15.

Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany. Electronic address:

View Article and Full-Text PDF

Whole genome and transcriptome analysis enhances precision cancer treatment options.

Ann Oncol 2022 Jun 9. Epub 2022 Jun 9.

Department of Medical Oncology, BC Cancer - Vancouver, Vancouver BC, Canada.

Background: Recent advances are enabling delivery of precision genomic medicine to cancer clinics. While the majority of approaches profile panels of selected genes or hotspot regions, comprehensive data provided by whole genome and transcriptome sequencing and analysis (WGTA) presents an opportunity to align a much larger proportion of patients to therapies.

Patients And Methods: Samples from 570 patients with advanced or metastatic cancer of diverse types enrolled in the Personalized OncoGenomics (POG) program underwent WGTA. Read More

View Article and Full-Text PDF

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Ann Oncol 2022 May 30. Epub 2022 May 30.

Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

View Article and Full-Text PDF

Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.

Ann Oncol 2022 Jun 8. Epub 2022 Jun 8.

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, PA, USA; Center for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, PA, USA. Electronic address:

Background: Anti-CD19 chimeric antigen receptor T-cell immunotherapy (CAR-T) is now a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas; however, a significant portion of patients do not respond to CAR-T and/or experience toxicities. Lymphodepleting chemotherapy is a critical component of CAR-T that enhances CAR-T cell engraftment, expansion, cytotoxicity, and persistence. We hypothesized that the lymphodepletion regimen might affect the safety and efficacy of CAR-T. Read More

View Article and Full-Text PDF

Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial.

Ann Oncol 2022 Jun 7. Epub 2022 Jun 7.

Department of Experimental Therapeutics, National Cancer Center Hospital Kashiwa, Japan.

Background: Prognosis of advanced gastrointestinal stromal tumors (GIST) refractory to tyrosine kinase inhibitors (TKIs) is poor. This randomized, placebo-controlled, phase 3 trial evaluated the efficacy and safety of pimitespib, a novel heat shock protein 90 inhibitor, in advanced GIST refractory to standard TKIs.

Patients And Methods: Patients with histologically confirmed GIST refractory to imatinib, sunitinib, and regorafenib were randomized 2:1 to oral pimitespib 160 mg/day or placebo for five consecutive days per week in 21-day cycles. Read More

View Article and Full-Text PDF

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.

Ann Oncol 2022 Jun 6. Epub 2022 Jun 6.

Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U1015/CIC1428, Université Paris Saclay, Villejuif, France.

Background: Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase 2 multicohort KEYNOTE-158 (NCT02628067) study. Herein, we report safety and efficacy outcomes with longer follow-up for more patients with previously treated advanced MSI-H/dMMR noncolorectal cancers who were included in cohort K of the KEYNOTE-158 (NCT02628067) study.

Patients And Methods: Eligible patients with previously treated advanced noncolorectal MSI-H/dMMR solid tumors, measurable disease per RECIST v1. Read More

View Article and Full-Text PDF

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.

Ann Oncol 2022 May 30. Epub 2022 May 30.

Département d'Innovation Précoce et d'Essais Thérapeutiques (DITEP), INSERM U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France; Department of Medicine, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France. Electronic address:

Background: Acetaminophen (APAP) use has been associated with blunted vaccine immune responses. This study aimed to assess APAP impact on immunotherapy efficacy in patients with cancer.

Patients And Methods: Exposure to APAP was assessed by plasma analysis and was correlated with clinical outcome in three independent cohorts of patients with advanced cancer who were treated with immune checkpoint blockers (ICB). Read More

View Article and Full-Text PDF

Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?

Ann Oncol 2022 May 27. Epub 2022 May 27.

Department of Medical Oncology, Rakuwakai-Otowa Hospital, Kyoto, Japan; Department of Medical Oncology, Showa-University, Tokyo, Japan.

View Article and Full-Text PDF

Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial.

Ann Oncol 2022 May 27. Epub 2022 May 27.

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Background: The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase 3 trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy.

Patients And Methods: A clinical grade whole-transcriptome assay was performed on RP samples obtained from patients enrolled in SAKK 09/10, a phase 3 trial of 350 men with biochemical recurrence post-radical prostatectomy randomized to 64Gy vs. Read More

View Article and Full-Text PDF

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

Ann Oncol 2022 May 20. Epub 2022 May 20.

Laboratory for Translational Breast Cancer Research (LTBCR), Department of Oncology, KU Leuven, 3000 Leuven, Belgium. Electronic address:

Background: Invasive Lobular breast cancer (ILC) is the second most common type of breast cancer after invasive breast cancer of no special type (NST), representing up to 15% of all breast cancers.

Design: Latest data on ILC are presented, focusing on diagnosis, molecular make-up according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) guidelines, treatment in the early and metastatic setting and ILC-focused clinical trials.

Results: At the imaging level, MRI-based and novel PET/CT-based techniques can overcome the limitations of currently used imaging techniques for diagnosing ILC. Read More

View Article and Full-Text PDF

Epstein-Barr virus DNA detection by targeted sequencing in post-treatment plasma samples and prognosis of locally advanced nasopharyngeal cancer: implications for clinical research.

Ann Oncol 2022 May 19. Epub 2022 May 19.

2(nd) Department of Internal Medicine, Oncology Unit, Attikon University Hospital, Athens, Greece. Electronic address:

View Article and Full-Text PDF

Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?

Ann Oncol 2022 May 12. Epub 2022 May 12.

Mount Vernon Cancer Centre, Northwood, Middlesex, UK.

View Article and Full-Text PDF

Bigger isn't always better: the ESMO dose de-intensification guideline framework.

C L Shapiro

Ann Oncol 2022 Jul 12;33(7):672-673. Epub 2022 May 12.

Icahn School of Medicine at Mt Sinai, New York, USA. Electronic address:

View Article and Full-Text PDF

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.

Ann Oncol 2022 Jul 9;33(7):702-712. Epub 2022 May 9.

INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, PRISM Center for Precision Medicine, Gustave Roussy, Villejuif, France. Electronic address:

Background: The landscape of clinical trials testing risk-adapted modulations of cancer treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority have been used; however, no consensus or convention has ever been agreed to categorise biomarkers useful to inform the treatment intensity modulation of cancer treatments.

Methods: An expert subgroup under the European Society for Medical Oncology (ESMO) Precision Medicine Working Group shaped an international collaborative project to develop a classification system for biomarkers used in the cancer treatment de-intensification, based on a tiered approach. Read More

View Article and Full-Text PDF

Deciphering radiological stable disease to immune checkpoint inhibitors.

Ann Oncol 2022 May 6. Epub 2022 May 6.

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical Center, New York, USA; Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

Background: 'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset of patients with SD who are benefiting from treatment. Understanding SD would facilitate drug development and improve precision in correlative research. Read More

View Article and Full-Text PDF

Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103 immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials.

Ann Oncol 2022 May 4. Epub 2022 May 4.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.

Background: High CD103 intratumoral immune cell (ITIC) abundance is associated with better prognosis in unselected patients with human papilloma virus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) treated with cisplatin and radiotherapy (CIS/RT). Substituting cetuximab (CETUX) for CIS with RT in HPV-associated OPSCC resulted in inferior efficacy. Our aim was to determine whether quantification of CD103 ITIC could be used to identify a population of HPV-associated OPSCC with superior prognosis. Read More

View Article and Full-Text PDF

Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.

Ann Oncol 2022 May 4. Epub 2022 May 4.

Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA. Electronic address:

View Article and Full-Text PDF

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.

Ann Oncol 2022 May 2. Epub 2022 May 2.

Departments of Surgery, University of California, San Francisco, USA.

Background: Difference in pathologic complete response (pCR) rate after neoadjuvant chemotherapy does not capture the impact of treatment on downstaging of residual cancer in the experimental arm. We developed a method to compare the entire distribution of residual cancer burden (RCB) values between clinical trial arms to better quantify the differences in cytotoxic efficacy of treatments.

Patients And Methods: The Treatment Efficacy Score (TES) reflects the area between the weighted cumulative distribution functions of RCB values from two trial arms. Read More

View Article and Full-Text PDF

First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report.

Ann Oncol 2022 Apr 30. Epub 2022 Apr 30.

Department of Radiotherapy, Shanxi Provincial Cancer Hospital, Taiyuan, China. Electronic address:

View Article and Full-Text PDF

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.

Ann Oncol 2022 Jul 28;33(7):674-684. Epub 2022 Apr 28.

Department of Medical and Surgical Specialties Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy.

View Article and Full-Text PDF

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma.

Ann Oncol 2022 Apr 29. Epub 2022 Apr 29.

Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories; Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories; Centre for Novostics, Hong Kong Science Park, New Territories; State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories. Electronic address:

Background: Quantitative measurement of plasma Epstein-Barr virus (EBV) DNA by real-time PCR at the end of primary treatment is a robust prognostic marker for nasopharyngeal carcinoma (NPC) patients. However, up to 40% of patients who would later develop disease recurrence had undetectable post-treatment plasma EBV DNA. Targeted sequencing for the entire EBV genome potentially allows a more comprehensive and unbiased detection of plasma EBV DNA and enables the use of other parameters such as fragment size as biomarkers. Read More

View Article and Full-Text PDF

Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.

Ann Oncol 2022 Apr 22. Epub 2022 Apr 22.

Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMI, IMIB, Murcia, Spain. Electronic address:

Background: The results of the RAPIDO trial have been accepted as evidence in favour of short-course radiotherapy (SC-RT) followed by chemotherapy before total mesorectal excision in high-risk locally advanced rectal cancer. A noteworthy concern is that the RAPIDO trial did not ensure that all patients in the control arm received adjuvant chemotherapy. This may bias statistical estimates in favour of the experimental arm if adjuvant chemotherapy is active in rectal cancer. Read More

View Article and Full-Text PDF